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A B S T R A C T
Hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurological disorders characterized pri-
marily by a pyramidal syndrome with lower limb spasticity, which can manifest as pure HSP or associated with a
number of neurological or non-neurological signs (i.e., complicated HSPs). The clinical variability of HSPs is
associated with a wide genetic heterogeneity, with more than eighty causative genes known. Recently, next
generation sequencing (NGS) has allowed increasing genetic definition in such a heterogeneous group of dis-
orders. We report on a 56- year-old man affected by sporadic complicated HSP consisting of a pyramidal syn-
drome, cerebellar ataxia, congenital cataract, pes cavus, axonal sensory-motor peripheral neuropathy and
cognitive decline. Brain MRI showed cerebellar atrophy and thin corpus callosum. By NGS we found a novel
homozygous biallelic c.452-1G > C mutation in the b-glucosidase 2 gene (GBA2), known to be causative for
autosomal recessive hereditary spastic paraplegia type 46 (SPG46). The rarity of this inherited form besides
reporting on a novel mutation, expands the genetic and clinical spectrum of SPG46 related HSP.
1. Introduction
Hereditary spastic paraplegias (HSPs) represent a clinically and
genetically heterogeneous group of neurodegenerative diseases [1].
Clinically, HSPs are defined as “pure” or “uncomplicated” forms if
neurological manifestations consist of an isolated pyramidal syndrome
with lower limb spasticity and weakness with or without bladder dis-
turbance and diminution of lower extremity vibration sensation [1].
“Complex” HSPs include other signs and symptoms as cerebellar ataxia,
peripheral neuropathy, optic atrophy, congenital cataract, epilepsy,
mental retardation, skeletal abnormalities, thin corpus callosum (TCC).
Inheritance may be autosomal dominant (AD), autosomal recessive
(AR), X-linked or maternally inherited by mitochondrial DNA. Among
all recognized HSPs, 79 are classified as spastic paraplegia (SPG1→ 79)
on online mendelian inheritance in man (OMIM). The majority of genes
are inherited by AR traits. The prevalence of AR-HSP was recently
calculated as 1.8/100.000, with SPG11 being the most frequent form,
followed by SPG15 [1]. Diagnostic genetic approach to such hetero-
geneous diseases has been considerably improved by next generation
sequencing (NGS). In this paper, we describe the first Italian patient
with SPG46 harboring biallelic novel mutations in b-glucosidase 2 gene
(GBA2).
2. Case presentation
The proband is a 56-year-old Italian man affected by a form of early-
onset complicated spastic paraplegia with non-consanguineous parents.
His father died for acute myocardial infarction at 50 and his mother is a
70-year-old healthy woman. The onset of disease was at the age of 6
with subtle impairment in maneuvering of the hands and associated
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postural-action tremor. Over the years, upper limbs dysmetria and
dysarthria were associated to progressive spastic ataxia. Patient com-
plained weakness, stiffness of the lower limbs and balance disorder,
requiring a crutch at 18 years. Bilateral cataract was diagnosed at age
28. The first brain MRI (at age 47) showed cerebellar atrophy, while
spinal cord MRI was normal. Genetic tests ruled out Spinocerebellar
ataxia (SCA) type 1 (SCA1, ATXN1), type 2 (SCA2, ATXN2), type 3
(SCA3, ATXN3), type 6 (SCA6, CACNA1A), type 7 (SCA7, ATXN7),
Friedreich Ataxia (FA, FXN), Ataxia talangiectasia (ATM), and Ataxia
with oculomotor apraxia type 1 (AOA1, APTX), as well as Niemann-Pick
type C (NPC1 and NPC2) by a cutaneous biopsy. Vitamin deficiencies,
endocrine and coeliac diseases and other metabolic abnormalities were
excluded as well. Intellectual development was normal in early child-
hood, without scholar or professional impact. Mild cognitive decline
was noticed at about age 49 and neuropsychological examination at age
52 showed executive functions and declarative memory impairment
and ideomotor apraxia.
Neurological examination on admission to our hospital (at age 52)
showed typical signs of spastic paraplegia, such as stiffness and weak-
ness of the lower limbs, brisk reflexes and bilateral extensor plantar
responses, spastic gait requiring a medical walker. There was associa-
tion with a cerebellar syndrome, characterized by ataxia, moderate
dysarthria and upper limbs intentional tremor. Oculomotor dysfunction
was present with saccadic pursuit, slow saccades and bilateral hor-
izontal nystagmus. Hypopallesthesia of ankles and bilateral pes cavus
were present. A motor axonal peripheral neuropathy was confirmed by
nerve conduction studies (decreased amplitude of compound muscle
action potential, mild slowing of conduction velocity and chronic de-
nervation, except for thoracic and brainstem regions), while a muscle
biopsy was normal. Serial brain and spinal MRIs showed stable cere-
bellar atrophy associated with TCC, without clear white matter or
brainstem involvement [Fig. 1].
Genomic DNA was extracted from peripheral blood samples ac-
cording to standard procedures, after receiving patient informed con-
sent. We tested for a panel of 89 known and exploratory spastic para-
plegia genes, by a Nextera Custom Enrichment panel (Illumina, San
Diego, Ca). We identified a novel homozygous mutation c.452-1G > C
in the b-glucosidase 2 gene (GBA2), not reported in available databases
(dbSNP146, 1000 Genomes, Exome Aggregation Consortium (ExAC),
NHLBI Exome Sequencing Project Exome Variant Server and gnomAD).
The same mutation, in heterozygosity, was detected in a peripheral
blood sample from the proband’s mother [Fig. 2]. No other variants
possibly associated to HSP were identified. Since the mutation is novel
and the parents are not consanguineous, we excluded the possibility of
a deletion of GBA2 on the paternal allele or maternal UPD of chro-
mosome 9 by the mean of high-density SNP array. cDNA QRT-PCR
showed a reduction of GBA2 mRNA expression levels of about 50%
compared with those of normal control in the proband’s mother and the
absence of GBA2 mRNA in the proband, demonstrating a complete
degradation of GBA2 mRNA transcribed from the mutated allele
Fig. 1. Brain MRI of SPG46 patient (homozygous mutation c.452-1G > C). A. Sagittal T1 weighted image showing a moderate cerebellar atrophy associated with thinning of the corpus
callosum body. B and D. Axial T1 weighted image and Axial T2-FLAIR weighted image demonstrating mild atrophy of the cerebellar hemispheres. C. Axial T2-FLAIR weighted image
showing mild and diffuse cortical atrophy without evident white matter changes (MRI quality reduced by motion artifacts).
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[Fig. 2D].
RT-PCR with primers located in GBA2 exons 1 and 5 revealed the
presence of the expected wild-type fragment (700 bp) in the normal
control and heterozygous mother, while no amplification was observed
in the proband [Fig. 2E].
3. Discussion
We report on the identification of a novel biallelic mutation in
GBA2, c.452-1G > C, located in the splice acceptor site of exon 3. The
identified variant produces a complete loss of GBA2 mRNA expression
caused by an altered splicing process generating an unstable transcript
that is rapidly degraded. This mutation should be considered causative
for this phenotype. Clinical presentation of our patient matches the
SPG46 phenotype [2,3]. In fact, an early-onset, slowly progressive
spastic paraplegia complicated by cerebellar ataxia with cerebellar
atrophy, bilateral cataract, intellectual deterioration, axonal neuro-
pathy and skeletal abnormalities is consistent with clinical manifesta-
tions so far reported in SPG46 [3]. GBA2 mutations are found also in
patients with progressive ataxia as the main symptom at onset in their
first two decades, associated successively with other features (GBA2-
related autosomal recessive cerebellar ataxia (ARCA) with spasticity)
[4]. So, sometimes, the different classification between cerebellar
ataxia and HSP can appear artificial, revealing instead a continuous
spectrum of phenotypes linked to some genes (first of all SPG7).
Characteristic brain MRI abnormalities (e.g., cerebellar atrophy and
TCC) were compatible with SPG46 [1]. Hypogonadism, that has also
been reported in SPG46 [1], was not present in our patient, excluded by
hormone blood test.
GBA2 is a non-lysosomal glucosylceramidase, localized on plasma
membrane and endoplasmic reticulum. This enzyme degrades gluco-
sylceramide to ceramide and glucose. While the lysosomal form of the
enzyme, GBA, is implicated in Gaucher disease, the relevance of GBA2
activity is less understood. GBA2-deficient mice present impaired liver
regeneration and male infertility, but it is not clear why they do not
develop spastic paraparesis or ataxia. However, alterations in lipid
metabolism are known as pathogenic mechanisms underlying several
HSPs, such as CYP7B1 (SPG5), B4GALTN1 (SPG26), DDHD1 (SPG28),
FA2H (SPG35), PNPLA6 (SPG44), CYP2U1 (SPG49/56), DDHD2
(SPG54). Lipid metabolism is involved in membrane composition and
its alteration may compromise the fluidity of the cell membrane. In
addition, organelle structure modification and intracellular trafficking
dysregulation are also linked to impairment of lipid metabolism. All
these features are known as potential factors of HSPs pathophysiology
[5].
4. Conclusion
Since few families affected by mutations in GBA2 gene have been
previously described [2,3,4], additional observations are interesting,
particularly if related to new mutations, in order to better delineate the
phenotype and the clinical spectrum. Moreover, our patient confirms
the importance of searching for genetic causes in apparently sporadic
individuals with spastic paraparesis, after a careful workup to exclude
acquired causes, and to disclose key neurological and non-neurological
signs in order to better address genomic analysis. However, the avail-
ability of a panel able to investigate in parallel an informative number
of genes seems greatly effective to find rare mutations especially in AR
or sporadic cases.
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Fig. 2. Mutation analysis. A. Family pedigree. B. The output bam files are visualized on
the Integrate Genome Viewer (IGV) software tool. Vertical dotter lines show the position
of the pathogenic GBA2 mutation (c.452-1G > C). C. Sanger sequencing of the patho-
genic mutation in proband and his mother. The arrows indicate the position of the mu-
tation. D. cDNA QRT-PCR shows the absence of GBA2 mRNA in the proband and a re-
duction of GBA2 mRNA expression levels of about 50% in his mother compared with
those of normal control. E. 2% agarose gel electrophoresis shows the presence of a single
fragment of about 700 bp in both control sample and heterozygous proband’s mother. L:
100 bp ladder; C: control; M: mother; P: proband; B: blank.
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